Follow-up: Consortium lowers the minimum acceptance condition in connection with offer for Bavarian Nordic from more than 90% to 75% of the shares (DKK 237.80, 0.00)
Bavarian Nordic's board unanimously recommends shareholders accept consortium's DKK233/share in cash offer (DKK 237.80, 0.00)
StreetAccount Sector Summary - Healthcare Post-Market
StreetAccount Sector Summary - Healthcare Pre-Market
FDA has suspended the BLA for Valneva's IXCHIQ; cites CBER's benefit-risk analysis ($11.64, 0.00)
Autos/Parts, Chemicals and Healthcare gain; Insurance, Real Estate and Utilities lag:
Bavarian Nordic A/S reports Q2 net income DKK362.6M, +39% vs year-ago DKK261.1M; narrows FY revenue expectations (DKK 238.60, 0.00)
StreetAccount M&A Summary: Week of 28-Jul
Bavarian Nordic A/S completes acquisition of Priority Review Voucher and raises FY EBITDA margin guidance (DKK 237.10, +1.10)
Powered by FactSet Research Systems Inc.